Within the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. With those rising numbers in mind, Bristol Myers Squibb is doubling down on treating the condition with a nearly $2 billion partnership with GentiBio to develop Treg therapies for patients with IBD.

Nearly one third of patients with ulcerative colitis who received an experimental Pfizer Inc. medicine in a clinical trial were in remission after a year of treatment, the drugmaker said on Tuesday.